Merriman Curhan Ford Initiates Coverage on Acorda Therapeutics (ACOR) with a Neutral
ACOR Hot Sheet
Rating Summary:3 Buy, 5 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Merriman Curhan Ford initiates coverage on Acorda Therapeutics (Nasdaq: ACOR) with a Neutral rating.
Merriman analyst says, "Acorda is poised on the cusp of an expected FDA panel hearing in several weeks and Priority Review for Fampridine-SR with a PDUFA date of October 22. As such, Acorda is one of a handful of companies with an expected product approval between now and year end, and the action in ACOR stock is exquisitely dependent upon the fortunes of Fampridine-SR. While we are encouraged by the product’s therapeutic profile and the addressable market, we are cautious on the shares in front of the upcoming FDA panel meeting based on our concerns over the perception of the drug’s risk/benefit profile in the eyes of the FDA and the members of the advisory committee. We are on the sidelines until October 12, when the panel briefing documents become available."
To see more analyst ratings on ACOR Click Here.
Merriman analyst says, "Acorda is poised on the cusp of an expected FDA panel hearing in several weeks and Priority Review for Fampridine-SR with a PDUFA date of October 22. As such, Acorda is one of a handful of companies with an expected product approval between now and year end, and the action in ACOR stock is exquisitely dependent upon the fortunes of Fampridine-SR. While we are encouraged by the product’s therapeutic profile and the addressable market, we are cautious on the shares in front of the upcoming FDA panel meeting based on our concerns over the perception of the drug’s risk/benefit profile in the eyes of the FDA and the members of the advisory committee. We are on the sidelines until October 12, when the panel briefing documents become available."
To see more analyst ratings on ACOR Click Here.
You May Also Be Interested In
Create E-mail Alert Related Categories
New CoverageRelated Entities
Merriman Curhan FordSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
